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access article under the CC BY-NC-NDSummary Background: Osteoarthritis (OA) is the most common degenerative joint disorder.
Inflammatory cytokine plays an important role in OA progression. Previous studies have demon-
strated that ginsenoside Rb1 would prevent inflammation and apoptosis in chondrocytes. How-
ever, we have not found any animal study reporting that Rb1 attenuates the severity of OA.
Objective: In this study, we used a rat anterior cruciate ligament transaction plus medial
meniscus resection (ACLT þ MMx) model of OA and a cell model, to investigate whether admin-
istration of ginsenoside Rb1 may attenuate the progression of arthritis.
Methods: In this in vivo study, 16-week-old male SpragueeDawley rats were divided into three
groups: Group 1 (sham control group), Group 2 (Rb1-treated group), and Group 3 (OA group). In
Groups 2 and 3, OA was induced in the right knee joint with ACLT þ MMx in rats. Then Group 2
received continuous infusion of ginsenoside Rb1 via osmotic mini-pumps implanted subcutane-
ously. At 4 weeks after treatment, the rats were sacrificed. Interleukin-1b (IL-1b) level was
evaluated by enzyme-linked immunosorbent assay (ELISA); cartilage damage was assessed
via histology (Safranin-O/fast green stain) and immunohistochemistry [matrix
metalloproteinase-13 (MMP13) and type X collagen (Col X)]. For cell study, C5.18 (rat chondro-
cyte cell line) was used in this research. The effect of Rb1 on IL-1b-induced MMP13 or Col X/F, Li Ka Shing Institute of Health Institute, Prince of Wales Hospital, The Chinese University of Hong
ong SAR, PR China.
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28 Y. Chen et al.expression level in C5.18 cells was investigated.
Results: In this in vivo study, characteristics of OA were present in the OA group, in contrast to
less severe damage generally observed in the Rb1 treatment group: first, IL-1b level was signif-
icantly decreased, and second, cartilage degeneration was attenuated, as indicated by lower
histologic damage scores and lower percentages of MMP13 or Col X-positive chondrocytes. In
the cell study, the results showed that Rb1 treatment would relieve the MMP13 or Col X expres-
sion in C5.18 cells induced by IL-1b.
Conclusion: In the present study, we demonstrated that Rb1 can attenuate the progression or
severity of arthritis by reducing inflammation.
ª 2016 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking
Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA) is one of the most common progressive
joint disorders affecting our elderly population. The con-
dition is pathologically characterized by cartilage degen-
eration, changes in subchondral bone matrix, and
secondary synovial inflammation. Clinical presentation
comprises pain, joint stiffness, and declining activity of
daily functions [1e3]. Inflammatory cytokine plays an
important role in OA progression [4e8]. For example,
studies have shown that these inflammatory cytokines,
including interleukin-1b (IL-1b) and stromal cell-derived-
factor 1, are involved in lubricin catabolism and cartilage
degeneration. Their mechanism resides in the upregulation
of matrix metalloproteinase-13 (MMP13) that has been
shown to cleave type II collagen and proteoglycans [5e8].
In addition, they can further inhibit the synthesis of the
main constituents of the extracellular matrix, type II
collagen, and aggrecan. These factors lead to the disrup-
tion of the normal articular cartilage homeostasis and the
eventual breakdown of cartilage in OA.
Current research and treatment focus on identifying a
method to regulate this mechanism, and thus, prevent or
delay the breakdown of the articular cartilage or regen-
erate it. A class of natural products such as steroid gly-
cosides and triterpene saponins, known as ginsenosides,
has been identified as the principal active components in
pharmacological studies of ginseng [9]. At the present
time, over 40 ginsenosides have been identified, which
show different biological activities based on structural
differences. The most abundant ginsenoside Rb1 has been
shown to have a variety of biological activities, including
anti-inflammatory, antiapoptotic, and neuroprotective
activities [10,11]. Previous in vitro studies have demon-
strated that Rb1 would prevent IL-1b- or hydrogen
peroxide (H2O2)-induced inflammation and apoptosis in
chondrocytes [12,13]. In an in vivo study, Endale et al [14]
proved that Rb1 would attenuate the severity of mouse
collagen-induced arthritis. However, the effect of ginse-
nosides in a degenerative animal model remains
unexplored.
The objective of this study is to investigate whether sys-
temic administration of ginsenoside Rb1 may attenuate OA
progression in a severe post-traumatic rat arthritis model.Materials and methods
Animal surgery
All experiments were approved by the Animal Research
Ethics Committee of the Chinese University of Hong Kong.
In this study, 16-week-old male SpragueeDawley rats,
weighing 450e500 g, were used. The animals were allo-
cated randomly into three groups. Group 1 involved an open
arthrotomy and sutured closure, this served as the sham
control (nZ 5). In Groups 2 and 3, the rats were subjected
to the anterior cruciate ligament transaction plus medial
meniscus resection (ACLT þ MMx) as described previously
[15]. In brief, each rat was anaesthetized with a solution of
0.2% (vol/vol) xylazine and 1% (vol/vol) ketamine in
phosphate-buffered saline (PBS), and after being shaved
and disinfected, the right knee joint was exposed through a
medial parapatellar arthrotomy approach. The patella was
dislocated laterally and the knee was placed in full flexion,
followed by anterior cruciate ligament (ACL) and medial
cruciate ligament (MCL) transection with microscissors and
resection of the medial meniscus. Group 2 is the Rb1-
treated group; rats of this group received continuous infu-
sion of ginsenoside Rb1 (PI & PI Technology Inc., Guangz-
hou, China) via osmotic mini-pumps (n Z 5); The osmotic
mini-pumps (model 2006; Alza Corporation, Mountain View,
CA, USA) were inserted into small subcutaneous pockets
over the dorsolateral thorax, created by blunt dissection
after a small incision (w1 cm). Prior to insertion, 200-mL
pump reservoirs were filled with Rb1 (300mM) dissolved in
pure ethanol. The average pumping rate of the mini-
osmotic pumps is 0.15 mL/h. Group 3 rats were left un-
treated and used as the OA controls (nZ 5). In accordance
with our animal ethics protocol, all the animal surgical
procedures were performed under general anaesthesia and
analgesic medications. After 4 weeks of treatment, all an-
imals were euthanized, and then the right knees of animals
were aspirated for analysis.
Blood collection and serum analysis
Blood (5 mL) was collected by cardiac puncture immedi-
ately after the animals were killed. The blood was centri-
fuged at 1800g for 10 minutes, and the separated serum
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of IL-1b in the serum was measured using the IL-1b enzyme-
linked immunosorbent assay (ELISA) kit (IL-1b ELISA kit, lot:
EK0393; Boster, Pleasanton, CA, USA).
Histology and immunohistochemistry
After disarticulation of the right joint, both femur and tibia
were dissected free of muscle and fixed in 10% formalin for
48 hours. Tibiae were then decalcified in 10% EDTA solution
for 21 days and embedded in paraffin. Serial 5-mm-thick
sagittal-oriented sections of the medial compartment of
the knee joint were cut at intervals of 0 mm, 100 mm, and
200 mm, and collected on glass slides [16]. The sections
were stained with Safranin-O/fast green. Cartilage degra-
dation was quantified by Osteoarthritis Research Society
International scores [17]. Three independent and blinded
observers scored each section. Immunostaining was per-
formed using a standard protocol. We incubated sections
with primary antibodies to rabbit MMP13 (1:50, ab3208;
Abcam, Cambridge, MA, USA) and collagen X (1:80,
ab58632; Abcam, Cambridge, MA, USA) overnight at 4C.
For immunohistochemical staining, a horse radish perox-
idaseestreptavidin detection system (Dako, Chai Wan,
Hong Kong) was subsequently used to detect the immu-
noactivity, followed by counterstaining with hematoxylin
(SigmaeAldrich, Poole, UK). Photographs of the selected
areas were taken by a light microscope (Leica DMRB; Leica
Cambridge Ltd, Cambridge, UK). We counted the number of
positively stained cells in the whole tibia cartilage or sub-
chondral bone area per specimen in three sequential sec-
tions (0 mm, 100 mm, and 200 mm) per rat in each group.
Cell experiment
C5.18 (rat chondrocyte cell line) was kindly gifted by Dr
Tong Weixue. These cells were maintained in complete
alpha-minimum essential medium (Invitrogen Corporation,
Carlsbad, CA, USA) supplemented with 10% foetal bovine
serum and 1% penicillinestreptomycineneomycin (com-
plete culture medium; all from Invitrogen Corporation,
Carlsbad, CA, USA) in a 5% CO2-humidified incubator at
37C.
For induction by MMP13 or type X collagen (Col X), cells
were transferred to serum-free DMEM (Dulbecco’s Modified
Eagle’s Medium, Invitrogen Corporation, Carlsbad, CA, USA)
and then treated with 10 ng/mL IL-1b (R&D Systems, Min-
neapolis, MN, USA) and Rb1 at 100 mg/mL. In the IL-1b
group, cells were treated with 10 ng/mL IL-1b alone. In the
control group, they were untreated except for a change in
the medium. Cells were harvested after incubation for 24
hours.
RNA extraction and quantitative real-time
polymerase chain reaction
Gene expression levels of MMP13 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) of C5.18 cells induced
by IL-1b were determined using real-time polymerase chain
reaction (RT-PCR). Total cellular RNA was isolated with RNA
Mini Kit (Invitrogen Corporation) and then reversetranscribed into cDNA using M-MLV Reverse Transcriptase
(Invitrogen Corporation) according to the manufacturer’s
instructions. RT-PCR was performed using the Step One Plus
Real-Time PCR System (Applied Biosystems, Hong Kong)
according to the manufacturer’s instructions. The reaction
conditions consisted of 15 mL reaction volumes. The relative
quantification of gene expression was analysed with 2-
DDCT method and normalized with GAPDH expression level.
The primers used are as follows: MMP13: forward (50e30)
TCCTGATGTGGGTGAATACAATG, reverse (50e30)
GCCATCGTGAAGTCTGGTAAAAT; GAPDH: forward (50e30)
GCATGGCCTTCCGTGTTC, reverse (50e030) GATGTCATCAT
ACTTGGCAGGTTT.
Immunofluorescent assay
Col X expression levels of C5.18 cells induced by IL-1b were
determined using an immunofluorescent stain. After in-
duction by IL-1b, the cells were placed in 4% para-
formaldehyde for 10 minutes and washed in phosphate-
buffered saline twice. Immunofluorescent staining was
performed using a standard protocol. We incubated the
cells with primary antibodies to rabbit collagen X (1:100,
ab58632; Abcam) overnight at 4C. Secondary antibodies
conjugated with fluorescence goat antirabbit CY3 (1:800;
Life Technologies, Warrington, UK) were added, and cells
were incubated at room temperature for 1 hour while
avoiding light, followed by counterstaining of cell nuclei
with 40,6-diamidine-20-phenylindole dihydrochloride (DAPI)
(Life Technologies, Warrington, UK). Photographs of the
selected areas were taken by a microscope (Leica DMRB;
Leica Cambridge Ltd, Cambridge, UK).
Statistical analysis
All statistical analyses were performed using the statistical
software SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
The data were analysed using one-way analysis of variance
(ANOVA). Assumptions of the analysis were assessed by the
ShapiroeWilk test of normality and Levene’s test for ho-
mogeneity of variance. The result of Levnene’s test was
used to determine the post hoc testing strategy. If not
significant, least significant difference test (LSD-t) post hoc
test was employed. If Levnene’s test was significant, the
analysis of variance was followed by Dunnett’s T3 post hoc
test for unequal variance. Values of p < 0.05 were
considered significant. Data were reported as
mean  standard deviation. The graphs were generated
using GraphPad Prism 6 (GraphPad Software, San Diego, CA,
USA).
Results
Ginsenoside Rb1 downregulates the level of IL-1b in
serum of rat ACLT D MMx OA models
ELISA result of IL-1b showed that the IL-1b level in the Rb1-
treated group (71.05  10.49 pg/mL, n Z 5, Figure 1) was
reduced significantly compared with that in the OA group
(118.69  17.58 pg/mL, n Z 5, p < 0.05, Figure 1). IL-1b
Figure 1 ELISA assay showing the IL-1b level in serum of the
three groups, 4 weeks after surgery. It showed that ginsenoside
Rb1 significantly downregulated the level of IL-1b, compared
with the OA group (n Z 5 per group). *p < 0.05.
ELISA Z enzyme-linked immunosorbent assay;
IL Z interleukin; OA Z osteoarthritis.
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(59.31  20.51 pg/mL, n Z 5, Figure 1). This result indi-
cated that Rb1 treatment would relieve secondary inflam-
mation in OA progression.Ginsenoside Rb1 attenuates cartilage degeneration
Safranin-O staining revealed serious OA lesions in the
cartilage in the OA group, with fewer OA changes being
observed in the Rb1-treated group (Figure 2A). The Osteo-
arthritis Research Society International scores in the OA
group reflected severe damage (14.86  1.03, n Z 5),
whereas cartilage damage in the Rb1-treated group was
significantly less (9.38  1.89, n Z 5, p < 0.05; Figure 2B),
compared with the OA group. The Osteoarthritis ResearchFigure 2 (A) Safranin-O and fast green staining of sagittal sect
articular cartilage was normal in the sham group. The Rb1-treated
the OA group has the most severe degenerative changes. Scale bar,
scores showed that cartilage degeneration in the OA group was mos
reduced the extent of cartilage damage; nZ 5 per group. *p < 0.05
OARSI Z Osteoarthritis Research Society International.Society International scores in the sham control group was
the lowest (1.5  0.41, n Z 5, Figure 2B).
Moreover, the percentages ofMMP13þ chondrocyteswere
lower in the Rb1-treated group (43.14 7.96, nZ 5) than in
the OA group (62.87  5.45, nZ 5, p < 0.05; Figures 3A and
3B). Likewise, the percentages of type X collagen-positive
chondrocytes of the Rb1-treated group (46.95  3.83,
n Z 5) were lower compared with those of the OA group
(64.6 2.48, nZ 5, p< 0.05; Figures 3A and 3C). In addition,
the percentages of MMP13þ or Col Xþ chondrocytes in the
sham control group were the lowest (24.74  3.51, nZ 5 or
27.26  2.53, nZ 5, respectively; Figures 3AeC).
These results indicate that Rb1 would attenuate carti-
lage degeneration in OA development.
Ginsenoside Rb1 inhibits MMP13 or Col X expression
in C5.18 cells induced by IL-1b
In the cell experiment, RT-PCR result showed that the
relative MMP13 mRNA level in the Rb1 group (6.28  1.45,
n Z 5, Figure 4) was reduced significantly compared with
that in the IL-1b group (20.11  5.89, n Z 5, p < 0.05,
Figure 4). In addition, MMP13 level in the control group was
the lowest (0.9536  0.04, n Z 5, Figure 4). Immunofluo-
rescent stain revealed that the number of Col X-positive
cells in the Rb1-treated group was fewer than that in the IL-
1b group. In the control group, the number of the Col X-
positive cells was the lowest (Figure 5).
These results indicated that Rb1 treatment would
relieve the MMP13 or Col X expression in C5.18 cells induced
by IL-1b.
Discussion
OA is a common and disabling disease, but the mechanisms
that drive this disease are not fully understood. However,
increasing evidencehas suggested that inflammatory cytokine
is a main regulator of OA progression [4e8]. It is widely
accepted that increased interleukin-1 beta (IL-1b) level plays
an important role in this process. For example, a high level ofions showing the subchondral tibia medial compartment. The
group showed fewer cartilage degenerative changes, whereas
400 mm (in top panels) and 200 mm (in bottom panels). (B) OARSI
t severe among the three groups, indicating that Rb1 treatment
, Rb1 group compared with the OA group. OAZ osteoarthritis;
Figure 3 (A) Representative images showing the immunostaining results of COL X and MMP13 in the articular cartilage regions of
the three groups; scale barZ 100 mm. (B) Semiquantitative analyses of the percentage of MMP13þ and COL X-positive chondrocytes
(brown) in the articular cartilage of the three groups. Results showed that Rb1 treatment significantly reduced the number of
MMP13þ and COL Xþ chondrocytes in the articular cartilage compared with that of the OA group; n Z 5 per group. *p < 0.05,
Rb1 group compared with the OA group. Col X Z type X collagen; MMP Z matrix metalloproteinase; OA Z osteoarthritis.
Figure 4 RT-PCR result showing the effect of Rb1 on IL-1b-
induced MMP13 gene expression. The normalized gene
expression levels are expressed as ratios of the copy number of
the mRNA and that of glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) cDNA. Results showed that Rb1 significantly
reduced the level of MMP13 gene expression in cells compared
with that of the IL-1b-induced expression; n Z 5 per group.
*p < 0.05, Rb1 group compared with the IL-1b group.
IL Z interleukin; MMP Z matrix metalloproteinase;
RT-PCR Z real-time polymerase chain reaction.
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stimulate the production of matrix metalloproteinases
(MMPs), Col X, cyclo-oxygenase-2, and prostaglandin E2.
These inflammatorycytokines can further inhibit the synthesis
of the main constituents of the extracellular matrix, type II
collagen, and aggrecan, and can disrupt the balance of
metabolism in the articular cartilage [4,18,19]. Furthermore,
it has been reported that apoptosis of chondrocytes can be
inducedby IL-1b [12], and chondrocyte apoptosis is thought to
haveapivotal role in humanandanimalOA [20]. Inour present
research, we have used an ACLTþMMxOAmodel of rats and a
cell model to study the benefits of ginsenoside Rb1 treatment
for OA. We have demonstrated that the level of Rb1 has a
positive effect of reducing the level of IL-1b. The cartilage
damage score and the expression of MMP13 or COL X in chon-
drocytes are dramatically decreased in the Rb1 treatment
group comparedwith those in the OA group. The results of the
cell experiments showed that Rb1 can inhibit IL-1b-induced
MMP13 or Col X expression in C5.18 cells. Taken together,
these results indicated that the use of ginsenoside Rb1 might
help chondrocytes regain their metabolic homeostasis.
Ginsenosides are unique saponins that exist only in
ginseng, and they have a variety of pharmacological ef-
fects, including anti-inflammatory, antiapoptotic, and
neuroprotective activities [10,11]. Ginsenoside Rb1 is most
abundant among more than 40 ginsenosides. In fact, some
researchers have demonstrated that ginsenoside Rb1 exerts
Figure 5 Immunofluorescent staining result showing the effect of Rb1 on IL-1b-induced Col X expression of C5.18 cells. This result
indicated that the number of Col X-positive cells (red) in the Rb1 group was significantly reduced compared with the cells induced
by IL-1b only. Scale bar, 400 mm. Col X Z type X collagen; IL Z interleukin.
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Cheng et al [12], using a human articular chondrocyte
model, found that Rb1 would prevent IL-1b-induced chon-
drocyte inflammation and apoptosis by decreasing the
levels of prostaglandin E2 (PGE2), nitrogen dioxide ion
(NO2), MMP13, cyclooxygenase 2 (COX-2), inducible nitric
oxide synthase (iNOS), and cysteine-aspartic acid protease-
3 (caspase-3), and by increasing Col2A1 gene expression
levels. Another study showed that Rb1 has some anti-
apoptotic effects on H2O2-treated chondrocytes by stabi-
lizing the mitochondria and caspase-3 inhibition [13]. Lee
et al [21] reported that Rb1 would inhibit MMP13 expression
in IL-1b-treated chondrocytes. In an in vivo study, Endale
et al [14] proved that in the mouse rheumatic arthritis
model, Rb1 would attenuate the severity of arthritis by
suppressing CD3þ/CD69þ, CD4þ/CD25þ, CD8þ T-cell,
CD19þ, B220/CD23þ B-cell, MHCIIþ/CD11cþ, and Gr-1þ/
CD11bþ cell activations and anti-CII or anti-RF immuno-
globulin G/immunoglobulin M, tumour necrosis factor-a, IL-
1, IL-17, and IL-6 secretions, but stimulate IL-10 levels in
the serum, joint, or splenocyte. Our present in vivo study is
the first to report that Rb1 treatment would attenuate
arthritis in an OA model. Our results are consistent with
other similar research works mentioned above. We found
that ginsenoside Rb1 shows the anti-inflammatory effect in
this OA rat model; by downregulating the inflammation the
severity of arthritis could be attenuated.
This study has some limitations: the number of animals
per group was relatively low; in addition to IL-1b, other OA
markers including MMP13 and MMP9 should also be used;
the level of MMP13 or Col X should be tested in the rat
chondrocytes by either RT-PCR or Western blot analysis.
Future research should consider using a large number of
animals in each group and a design to test multiple panels
of OA markers at multiple time points.
In conclusion, we have studied the benefits of ginseno-
side Rb1 treatment in a rat OA model and a cell model. We
demonstrated that Rb1 can attenuate the severity of
arthritis by reducing inflammation. These results imply that
ginsenoside Rb1 may be a potentially useful drug for the
treatment of OA patients.Conflicts of interest
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